While these TAM-associated biomolecules (CD47, CD68, and CD163) negatively affect overall survival in NPC, CD163 has emerged as a particularly significant biomarker due to its exceptional predictive value, suggesting its potential as a promising target in clinical research involving ADCs. This evidence concerns the gene CD68 and nasopharyngeal carcinoma.